Comparing LakeShore Biopharma (NASDAQ:LSB) and Cidara Therapeutics (NASDAQ:CDTX)

LakeShore Biopharma (NASDAQ:LSB) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for LakeShore Biopharma and Cidara Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LakeShore Biopharma	0	0	0	0	0.00
Cidara Therapeutics	0	0	8	1	3.11

Cidara Therapeutics has a consensus target price of $64.1429, suggesting a potential downside of 1.64%. Given Cidara Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cidara Therapeutics is more favorable than LakeShore Biopharma.

Insider & Institutional Ownership

52.6% of LakeShore Biopharma shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 3.9% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

LakeShore Biopharma has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Profitability

This table compares LakeShore Biopharma and Cidara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LakeShore Biopharma	N/A	N/A	N/A
Cidara Therapeutics	N/A	-50.81%	-42.46%

Earnings and Valuation

This table compares LakeShore Biopharma and Cidara Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LakeShore Biopharma	$85.67 million	0.19	-$13.93 million	N/A	N/A
Cidara Therapeutics	$1.27 million	1,302.15	-$169.83 million	($11.13)	-5.86

LakeShore Biopharma has higher revenue and earnings than Cidara Therapeutics.

Summary

Cidara Therapeutics beats LakeShore Biopharma on 7 of the 12 factors compared between the two stocks.

About LakeShore Biopharma

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

About Cidara Therapeutics

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.